Novacyt S.A. - London Vet Show: Launch of animal multiplex assays

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Launch of new animal multiplex assays at London Vet Show

Rapid, accurate detection of six gastrointestinal disease-causing pathogens in cats and dogs

Paris, France, Eastleigh and Manchester, UK - 14 November 2024 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it is launching two new assays for gastrointestinal disease in dogs and cats at the London Vet Show, held from 14-15 November 2024.

The genesig®PLEX kits for Canine and Feline Gastrointestinal (GI) Diseases are multiplexed qPCR assays that detect six disease-causing pathogens in the digestive system of cats and dogs in a two-tube assay, delivering a streamlined and efficient testing solution for centralised veterinary laboratories. Each target has been carefully selected to detect a key pathogen that can cause potentially serious or life-threatening GI illnesses in cats and dogs.

Testing for six pathogens using one sample will reduce hands-on time for laboratory technicians as well as the use of consumables. The kits provide results in less than three hours, enabling quicker, more comprehensive results to the veterinarian and ensuring faster treatment for the family pet.

If you are attending the London Vet Show and would like further information on the new genesig®PLEX kits for Canine and Feline Gastrointestinal (GI) Diseases, or Novacyt's wider portfolio of veterinary assays, the Novacyt team can be found at Booth No A49.

Lyn Rees, CEO of Novacyt, said: "Following consultation with our customers and further market research, we saw clear demand in the veterinary industry for multiplex assays that target several companion animal pathogens using a single sample. With the launch of our two new genesig®PLEX kits for cats and dogs, we are making testing for these gastrointestinal pathogens more cost-effective, faster and less hands-on for laboratories, and enabling quicker results for veterinarians.

"Adding to the 200+ veterinary assays in Primer Design's existing portfolio, these tests demonstrate our continued commitment to identifying emerging diagnostic needs and providing best-in-class solutions for our customers."

Contacts

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Eastleigh and Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

About the London Vet Show

The London Vet Show is Europe's largest veterinary conference and exhibition. Run with education partners the Royal Veterinary College and British Veterinary Association, the London Vet Show brings together thousands of veterinary professionals, innovators and industry giants, with over 400 exhibitors and 200 speakers.